People: Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23 Aug 2019
Change (% chg)

$-2.22 (-8.53%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Okey, Stephanie 

Ms. Stephanie S. Okey M.S. is the Independent Director of Albireo Pharma Inc. Ms. Okey has served as a member of our board of directors since June 2018. For over 25 years, from 1987 until July 2015, Ms. Okey served in various positions of increasing responsibility in the biopharmaceutical industry, first at Genentech, Inc., followed by 19 years at Genyzme, a Sanofi company. Ms. Okey's management experience during her tenure at Genyzme included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases from August 2012 to July 2015 and as Vice President and General Manager, U.S. Genetic Diseases Business Unit from September 2011 to August 2012. Ms. Okey retired from Genzyme, a Sanofi company, in July 2015. Ms. Okey is currently a member of the board of directors of PTC Therapeutics, Inc., a publicly traded biopharmaceutical company. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey holds a B.S. in Zoology from The Ohio State University and a M.S. in Immunology and Medical Microbiology from Wright State University.

Basic Compensation

Total Annual Compensation, USD 23,935
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 371,025
Fiscal Year Total, USD 394,960

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Chiswell


Ronald Cooper


Simon Harford


Jan Mattsson


Martha Carter


Patrick Horn

As Of  31 Dec 2018